

MAVENCLAD (Cladribine Tablets) Presentations

		Abstract/ Poster #	Presentation Date/Time/Session
Title	Lead Author		
Effects of Cladribine Tablets on CD4+ T Cel Subsets in the ORACLE-MS Study: Results from an Analysis of Lymphocyte Surface Markers	Stuve O	P667	Poster Session 1 Thursday 26 October 2017 Time: 15:30-17:00
Cladribine Tablets Produce Selective and Discontinuous Reduction of B and T Lymphocytes and Natural Killer Cells in Patients with Early and Relapsing Multiple Sclerosis (ORACLE-MS,CLARITY and CLARITY Extension)	Stuve O	P690	
Rates of Lymphopenia Year-by-year in Patients with Relapsing Multiple Sclerosis Treated and Retreated with Cladribine Tablets 3.5mg/kg	Cook S	P666	
Long-Term Lymphocyte Counts in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) Treated with Cladribine			

Tablets 3.5 mg/kg: Total

Lymphocytes, B and T Cell

Soelberg-Sorensen

Subsets

P

P655

-

Effects of Cladribine

Poster Session 2

Tablets on Radiological

Friday 27 October 2017

Outcomes in High Disease

Time: 15:30-17:00

Activity (HDA) Subgroups

of Patients with Relapsing

Poster Session 2

Multiple Sclerosis (RMS)

Friday 27 October 2017

in the CLARITY Study

Giovannoni G

P1164

Time: 15:30-17:00

Proportions of Patients

with Highly Active RMS

Achieving No Evidence of

Disease Activity (NEDA) in

Response to Cladribine

Tablets in CLARITY

Giovannoni G

P1143

Investigation of

Cladribine Treatment Rules

in Subjects with

Relapsing-Relmitting

Multiple Sclerosis (RRMS)

by means of Modelling &

Simulation

Terranova N

P912

Infections During Periods

of Grade 3 or 4

Lymphopenia in Patients

Taking Cladribine Tablets

3.5 mg/kg: Data from an

Integrated Safety Analysis Cook S

P1142

Innate Immune Cell Counts

in Patients with

Relapsing-Remitting

Multiple Sclerosis (RRMS)

Treated with Cladribine

Tablets 3.5 mg/kg in

CLARITY and CLARITY

Extension

Soelberg-

Sorensen P

P1141

-

An analysis of malignancy

risk in the clinical

development programme of

cladribine tablets in

patients with relapsing

multiple sclerosis (RMS)

Galazka A

P1878

-

Pregnancy outcomes during

the clinical development

programme of cladribine in

multiple sclerosis (MS):

an integrated analysis of

safety for all exposed

patients

Galazka A

P1874

-

Rebif (interferon beta-1a) Presentations

Abstract/

Presentation

Title

Lead Author

Poster #

Date/Time/Session

-

Disease Activity as

Poster Session 1

Assessed by the MAGNIMS

Thursday 26 October

Score Predicts Long-Term			2017
Clinical Disease Activity			Time: 15:30-17:00
Free Status and Disability			Poster Session 1
Progression in Patients			Thursday 26 October
Treated with Subcutaneous			2017
Interferon Beta-1a	Sormani MP	P770	Time: 15:30-17:00
The Association between			
Disease Activity and			
Disability Progression in			
Patients with			
Relapsing-Remitting			
Multiple Sclerosis	Spelman T	P348	
Clinical Characteristics			
and Treatment Patterns of			
Relapsing-Remitting			
Multiple Sclerosis			
Patients with High Disease			
Activity	Spelman T	P340	
Comparing patient and			
healthcare professional			
perceptions on multiple			
sclerosis management and			
care where do their			
priorities differ? Results			
from a qualitative survey	Rieckman P	P814	
Infertility Diagnosis and			
Treatment in Women With			
and Without Multiple			
Sclerosis	Houtchens MK	AP356	
Validation of MUSIQOL			

among Arabic-speaking MS

Patients treated with High

dose INF-beta 1a sc

injection New Formulation

Al Jumah M

P821

RebiQoL: A telemedicine

patient support program on

health related quality of

life and adherence in MS

patients treated with

Rebif

Landtblom AM

P826

Serum Neurofilament light

chain correlates with

disease activity and

predicts clinical and MRI

outcomes in MS

Barro C

P636

-

Impact of the Presence of

Gadolinium-Enhancing

Lesions at Baseline on No

Evidence of Disease

Activity Status in

Patients Treated with

Subcutaneous Interferon

Beta-1a: A Post-Hoc

Analysis of REFLEXION

Freedman M

P1144

Evolution of New Lesions

and its Temporal Patterns

in Patients with

Clinically Isolated

Syndrome Treated with

Poster Session 2

Friday 27 October 2017

Time: 15:30-17:00

Poster Session 2

Friday 27 October 2017

Time: 15:30-17:00

Subcutaneous Interferon

Beta-1a

Vrenken H

P1025

Using algorithms to
identify High Disease
Activity

Relapsing-Remitting

Multiple Sclerosis

patients using electronic
health record data with
natural language

processing

Kamauu AW

P877

Using United States

Integrated Delivery

Network (IDN) Electronic

Health Records

(EHR)/Natural Language

Processing (NLP)-Based

Algorithms to Identify

Relapses in

Relapsing-Remitting

Multiple Sclerosis (RRMS)

Patients

Kamauu AW

P885

Developing United States

Integrated Delivery

Network (IDN) Claims-Based

Algorithms to Identify

Relapses in

Relapsing-Remitting

Multiple Sclerosis (RRMS)

Patients

Kamauu AW

P878

Rates of Pregnancy in Women With and Without Multiple Sclerosis Over Time	Houtchens MK	P890
Prevalence of Comorbidities in Patients With and Without Multiple Sclerosis by Age and Sex: A US Retrospective Claims Database Analysis	Kresa-Reahl K	P941
Infertility Treatment and Live Birth Rates in Women With and Without Multiple Sclerosis	Houtchens MK	P891
An Evaluation of Adherence Using Panel Survey Data From Patients With Multiple Sclerosis Treated With Subcutaneous Interferon beta-1a or Dimethyl Fumarate	Perrin Ross A	P1251
Real-World Assessment of Relapse in Patients With Multiple Sclerosis Newly Initiating sclFNbeta1a Compared With Oral Disease-Modifying Drugs	Bowen J	P1245
Interferon-beta and regulatory cells: evaluation of		

treatment-induced modulation of Treg, Breg and CD56bright NK cell levels in multiple sclerosis patients	Martire S	P1140	
-			
Risk of stroke in patients with multiple sclerosis treated with subcutaneous interferon beta-1a	Venkatesh S	P1918	Late-breaker Poster Session 2 Friday 27 October 2017 Time: 15:30-17:00
Creating a healthcare claims-based adaptation of Kurtzke Functional Systems Scores for assessing multiple sclerosis severity and progression	Le Truong CTL	EP1767	ePosters
A mapping study to compare the educational offerings for patients in the fields of multiple sclerosis and HIV in Europe and Canada	Rieckman P	EP1838	
Long-term real-life retrospective analysis on interferon beta1-a use in RRMS patients in Finland	Al Jumah M	EP1687	
Adherence, cognition and behavioral performance in relapsing-remitting MS (RRMS) patients using the electronic autoinjector			

RetainSmart™: 1 and 2

year follow-up from the

German multicenter

RETAINsmart study

Rau D

EP1692

Cerebrospinal fluid levels

of neurofilament light

chain, C-X-C ligand motif

13, and chitinase-3-like

protein 1 reflect distinct

pathological processes in

multiple sclerosis

Zanoni M

EP1598

Brain atrophy and disease

free status over 3 years

in multiple sclerosis

patients under interferon

beta 1a subcutaneous

treatment

Rojas JI

EP1657

Evobrutinib Presentations

Abstract/ Presentation

Title

Lead Author

Poster # Date/Time/Session

-

Oral Presentation

B cell-mediated

Parallel Session 8:

experimental CNS

Immune Cells in Injury

autoimmunity is modulated

and Repair

by inhibition of Bruton's

Thursday 26 October 2017

tyrosine kinase

Torke S

143

14:00-15:30

Design of a Phase II Dose

Poster Session 1

Range Finding, Efficacy

Thursday 26 October 2017

and Safety Study of the
Bruton's Tyrosine Kinase
Inhibitor Evobrutinib
(M2951) in Relapsing
Multiple Sclerosis

Time: 15:30-17:00

Patients

Montalban X

P675

T cell mediated
experimental CNS
autoimmunity induced by
PLP in SJL mice is
modulated by Evobrutinib
(M2951) a novel Bruton's
tyrosine kinase inhibitor

Boschert U

P678